Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + trastuzumab + CapeOX first-line for HER2-positive advanced gastric cancer
ChiCTR2000039886Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, trastuzumab, capecitabine and oxaliplatin in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Zhejiang University. Primary endpoint: Objective response rate. Started Nov 2020; status: recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000039886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039886.